Erin Wilson
Stock Analyst at Morgan Stanley
(0.86)
# 3,204
Out of 4,667 analysts
19
Total ratings
50%
Success rate
-7.6%
Average return
Main Sectors:
Stocks Rated by Erin Wilson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RPD Rapid7 | Maintains: Equal-Weight | $46 | $41.06 | +12.03% | 4 | Jul 10, 2024 | |
| ALGN Align Technology | Maintains: Outperform | $715 → $732 | $223.87 | +226.98% | 3 | Jul 29, 2021 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $352 → $385 | $187.90 | +104.90% | 1 | Jul 20, 2021 | |
| IQV IQVIA Holdings | Maintains: Outperform | $242 → $265 | $194.38 | +36.33% | 1 | Jul 20, 2021 | |
| MEDP Medpace Holdings | Maintains: Outperform | $200 → $205 | $326.09 | -37.13% | 1 | Jul 20, 2021 | |
| ICLR ICON Public Limited Company | Maintains: Outperform | $245 → $250 | $203.67 | +22.75% | 2 | Jul 20, 2021 | |
| ELAN Elanco Animal Health | Upgrades: Outperform | $33 → $38 | $13.44 | +182.74% | 1 | Feb 26, 2021 | |
| FLGT Fulgent Genetics | Downgrades: Underperform | n/a | $17.28 | - | 1 | Jan 8, 2021 | |
| TMO Thermo Fisher | Initiates: Neutral | $341 | $512.84 | -33.51% | 1 | Jan 22, 2020 | |
| INCR InterCure | Maintains: Outperform | $68 → $54 | $1.33 | +3,948.28% | 4 | Nov 14, 2017 |
Rapid7
Jul 10, 2024
Maintains: Equal-Weight
Price Target: $46
Current: $41.06
Upside: +12.03%
Align Technology
Jul 29, 2021
Maintains: Outperform
Price Target: $715 → $732
Current: $223.87
Upside: +226.98%
Charles River Laboratories International
Jul 20, 2021
Maintains: Neutral
Price Target: $352 → $385
Current: $187.90
Upside: +104.90%
IQVIA Holdings
Jul 20, 2021
Maintains: Outperform
Price Target: $242 → $265
Current: $194.38
Upside: +36.33%
Medpace Holdings
Jul 20, 2021
Maintains: Outperform
Price Target: $200 → $205
Current: $326.09
Upside: -37.13%
ICON Public Limited Company
Jul 20, 2021
Maintains: Outperform
Price Target: $245 → $250
Current: $203.67
Upside: +22.75%
Elanco Animal Health
Feb 26, 2021
Upgrades: Outperform
Price Target: $33 → $38
Current: $13.44
Upside: +182.74%
Fulgent Genetics
Jan 8, 2021
Downgrades: Underperform
Price Target: n/a
Current: $17.28
Upside: -
Thermo Fisher
Jan 22, 2020
Initiates: Neutral
Price Target: $341
Current: $512.84
Upside: -33.51%
InterCure
Nov 14, 2017
Maintains: Outperform
Price Target: $68 → $54
Current: $1.33
Upside: +3,948.28%